Total: 2076

    Management of premenstrual Disorders ACOG clinical practice guideline nº 7

    Obstet. gynecol; 142 (6), 2023
    To provide recommendations for the management of premenstrual syndrome and premenstrual dysphoric disorder, collectively referred to as premenstrual disorders, based on assessment of the evidence regarding the safety and efficacy of available treatment options. An overview of the epidemiology, pathophysi...

    Perinatal mental health conditions: a national clinical guideline

    It is well recognised that perinatal mood disorders are common conditions affecting pregnancy and the postnatal period, and are associated with significant maternal, fetal and infant morbidity and mortality.1 Inequality in maternal morbidity and mortality is recognised across a number of socioeconomic in...

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Inactivated Vero Cell Culture-derived Japanese Encephalitis Vaccine in Children

    MMWR recomm. rep; 62 (45), 2023
    Inactivated Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [manufactured as IXIARO]) is the only JE vaccine licensed and available in the United States. JE-VC is manufactured by Intercell Biomedical (Livingston, United Kingdom) and distributed in the United States private market by Novart...

    CDC recommendations for hepatitis C testing among perinatally exposed infants and children: United States, 2023

    MMWR recomm. rep; 72 (4), 2023
    The elimination of hepatitis C is a national priority (https://www.hhs.gov/sites/default/files/Viral-Hepatitis-NationalStrategic-Plan-2021-2025.pdf). During 2010–2021, hepatitis C virus (HCV) acute and chronic infections (hereinafter referred to as HCV infections) increased in the United States, conseq...

    Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up

    Ann. oncol; 34 (11), 2023
    The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early diagnosis and an ability to identify and screen high-risk populations before symptoms arise. Identification of a high-risk population is challenging and optimal screening tools remain unclear.1 Older age is the str...

    Recurrent miscarriage: green-top guideline nº 17

    BJOG; 130 (12), 2023
    The purpose of this guideline is to provide guidance on the investigation and care of women and people with recurrent miscarriage.Within this document we use the terms woman and women's health. However, it is important to acknowledge that it is not only women for whom it is necessary to ...

    Antiplatelets and antithrombotics in neurointerventional procedures: guideline update

    J Neurointerv Surg; 15 (11), 2023
    Antiplatelet and antithrombotic medication management before, during, and after neurointerventional procedures has significant practice variation. This document updates and builds upon the 2014 Society of NeuroInterventional Surgery (SNIS) Guideline ’Platelet function inhibitor and platelet function te...

    Assessment, diagnosis, care and support for people with dementia and their carers - 2023

    Dementia is a clinical syndrome of cognitive decline that includes a range of cognitive and behavioural symptoms caused by a variety of underlying pathophysiological processes. This includes Alzheimer’s disease, vascular dementia, mixed dementia, dementia with Lewy bodies and frontotemporal dementia.1,...

    Compounded bioidentical menopausal hormone therapy ACOG clinical consensus nº 6

    Obstet. gynecol; 142 (5), 2023
    Many compounding pharmacies use the phrase “bioidentical hormone” as a marketing term to imply that these preparations are natural and, thus, safer and more effective than U.S. Food and Drug Administration (FDA)–approved menopausal medications that use bioidentical or synthetic hormones or both. Ho...